Glyceryl monolaurate

Glyceryl Monolaurate (Monolaurin): A Comprehensive Reference

1. Identity

Chemical Names and Synonyms

Monolaurin (also called glycerol monolaurate, glyceryl laurate, and 1-lauroyl-glycerol) is a monoglyceride. Its synonyms include: 2,3-Dihydroxypropyl dodecanoate, 1-Monolaurin, Lauricidin, Glyceryl laurate, Glycerol 1-laurate, 1-Monolauroyl-rac-glycerol, 1-Monododecanoylglycerol, Glycerol monolaurate, Laurin 1-mono-, Lauric acid 1-monoglyceride, Dodecanoic acid 2,3-dihydroxypropyl ester, and DL-alpha-Laurin.

It is the mono-ester formed from glycerol and lauric acid. Its chemical formula is C₁₅H₃₀O₄. Its CAS Number is 27215-38-9, its EC Number is 248-337-4, and its molecular weight is 274.4. In its pure form, glycerol monolaurate (GML) is an off-white solid. As a food emulsifier, it has an HLB (hydrophilic-lipophilic balance) value of 5.2.

Natural Sources

GML is naturally found in breast milk, coconut oil, and American sylvestris. Lauric acid, the component fatty acid of GML, is a medium-chain fatty acid most commonly sourced from coconut oil and palm kernel oil, both of which contain high concentrations of this fatty acid. Lauric acid can be ingested in coconut oil, and the human body converts it into monolaurin. Furthermore, coconut oil, coconut cream, grated coconut, and other products are sources of lauric acid and, consequently, monolaurin.

Human milk contains approximately 3,000 µg/mL of monolaurin; cow's milk has approximately 150 µg/mL; most foods (coconut and palm oil) have only trace, variable amounts. Commercially, monolaurin is generally not extracted from milk. Instead, manufacturers synthesize monolaurin from plant oils that are rich in lauric acid (mainly coconut and palm-kernel oils).

Common Forms and Preparations

Monolaurin typically appears on product labels as "Monolaurin," "Glycerol Monolaurate," or "Glyceryl Laurate." Glycerol, a simple sugar alcohol, is typically derived from plant oils or as a byproduct of biodiesel and soap production. Through an esterification process, lauric acid and glycerol are chemically combined to produce glycerol monolaurate.

Monolaurin is most commonly used as a nonionic surfactant and preservative in cosmetics and packaged foods. Monolaurin is also marketed as a dietary supplement. In pharmaceutical and topical research applications, GML is also formulated as non-aqueous gels (typically 5% GML concentration) for intravaginal and wound-dressing applications.

2. Traditional and Historical Use

Historically, the individual components of GML—particularly lauric acid—have long been recognized for their antimicrobial properties. This fatty acid has been used as a germicidal agent for centuries. The antimicrobial properties of volatile aromatic oils and medium-chain fatty acids derived from edible plants have been recognized since antiquity.

Monolaurin was originally discovered when microbiologists studied human breast milk to determine the antiviral substances that protected infants from microbial infections. It has been shown to protect newborns, whose immune systems are underdeveloped, from Respiratory Syncytial Virus (RSV) and other respiratory tract viruses. The recognized presence of GML in human breast milk — a food source with millennia of use — represents the oldest and most fundamental context for its consumption, though GML's specific identification within breast milk is a development of modern analytical science rather than a formally documented traditional medicine system.

GML as an isolated or concentrated compound does not have a documented history of use in formal traditional medicine systems (such as Ayurveda, Traditional Chinese Medicine, or Western herbalism) in the way that whole-plant preparations do. Its recognition and deliberate application are largely products of twentieth-century food chemistry and microbiology, beginning with the systematic characterization of medium-chain fatty acids and their derivatives in the mid-twentieth century.

3. Key Constituents and Established Mechanisms of Action

Chemical Nature

GML, also known as monolaurin, is a monoglyceride formed through the esterification of glycerol and lauric acid. It is a fatty acid with 12 carbons (C12) derived from plant-based sources such as palm kernel oil. GML is a type of lipophilic nonionic surfactant, which naturally exists in breast milk and palmetto, a type of palm tree.

Antimicrobial Mechanism

Several published studies indicate that monolaurin's primary mechanism of action is the insertion of its fatty acid 12-carbon chain into the microorganism's plasma membrane, thus interfering with plasma membrane signal transduction and transcription. The widely recognized action mode is that the hydroxyl group in the monoglyceride is adsorbed to the polar part of the cell membrane surface with the acyl carbon chain inserting into the hydrophobic region of the membrane, then moving across the phospholipid bilayers driven by the hydrophobic interaction, resulting in cell membrane perforation and final cell death.

GML suppresses the growth and virulence of numerous gram-positive and gram-negative bacteria, fungi, and enveloped viruses. At concentrations below those that are bactericidal, GML can inhibit the production and the effects of several gram-positive bacterial toxins in vitro. These include staphylococcal enterotoxins, toxic shock syndrome toxin 1 (TSST-1), and anthrax toxin.

Yearlong passage of Staphylococcus aureus MN8 on sub-growth-inhibitory concentrations of GML did not produce any increase in resistance to GML's antimicrobial and anti-exotoxin effects. This absence of observed resistance development is mechanistically consistent with the compound's membrane-disrupting mode of action, which does not target a single mutable molecular receptor.

Antiviral Mechanism

Purified and human milk-derived monoglycerides provide antiviral activity against enveloped viruses, including herpes simplex virus 1 (HSV-1) and HSV-2, vesicular stomatitis virus (VSV), and visna virus, but are ineffective against nonenveloped picornaviruses, including poliovirus and rhinovirus. The selectivity of GML's antiviral activity for enveloped viruses is explained by the same lipid-membrane disruption mechanism: enveloped viruses possess a lipid bilayer that is susceptible to insertion by GML's acyl chain, while non-enveloped viruses lack this target.

Immunomodulatory Mechanism

Researchers have mechanistically examined whether GML affects the signaling and functional output of human primary T cells. They found that GML potently altered order and disorder dynamics in the plasma membrane, resulting in reduced formation of LAT, PLC-γ, and AKT microclusters. Altered membrane events induced selective inhibition of TCR-induced phosphorylation of the regulatory P85 subunit of PI3K and AKT, as well as abrogated calcium influx. Ultimately, GML treatment potently reduced TCR-induced production of IL-2, IFN-γ, TNF-α, and IL-10.

In addition to its direct effects on pathogens, monolaurin stabilizes animal and human cell membranes to interfere with the damaging effects of bacterial exotoxins, endotoxins, and hypotonic solutions, including reduction of chemokines (IL-8, MIP-3α) that cause vaginal inflammation.

Anti-Biofilm Activity

GML is a natural surfactant with antimicrobial properties. At approximately 0.3 mM, both GML and its component lauric acid were bactericidal for antibiotic-resistant Staphylococcus aureus biofilms. With the use of MICs of antibiotics obtained from planktonic cells, GML and lauric acid acted synergistically with gentamicin and streptomycin, but not ampicillin or vancomycin, to eliminate detectable viable biofilm bacteria.

4. Scientific Evidence by Area of Use

4.1 Antibacterial Activity

GML is known for its antimicrobial properties, primarily against Gram-positive bacteria, with limited evidence of efficacy against Gram-negative pathogens. However, more recent work has extended its recognized spectrum. Contrary to previous reports, one 2025 study demonstrated that GML exhibits significant antibacterial activity against Gram-negative bacteria, including strains resistant to conventional antibiotics. It inhibited carbapenem-resistant isolates with MIC values ranging from 25 to 100 μg/mL for E. coli, K. pneumoniae, and E. cloacae, and showed bacteriostatic and bactericidal activity.

GML has strong antibacterial and antiviral effects, which could inhibit the growth and reproduction of Staphylococcus aureus, Escherichia coli, Bacillus, Salmonella, and Bacillus anthracis. GML is a broadly antimicrobial fatty acid monoester, killing bacteria, fungi, and enveloped viruses. The compound kills stationary-phase cultures of Bacillus anthracis, suggesting that the molecule may kill spores.

Evidence Strength: The antibacterial evidence is predominantly in vitro (laboratory/cell culture). There are limited controlled human trials examining oral GML as an antibacterial agent.

4.2 Antiviral Activity

GML protected against high-dose SIV infection and reduced inflammation, which can exacerbate disease, during infection. GML was also found to inhibit HIV-1 and other human-pathogenic viruses (yellow fever virus, mumps virus, and Zika virus), broadening its antimicrobial range.

GML was safe for chronic use (50 mg/mL) in Rhesus Macaque and protected against repeated intravaginal infection by high doses of simian immunodeficiency virus (SIV). These preclinical primate studies are the strongest available evidence for antiviral efficacy in a living mammalian system, but direct controlled trials in HIV-positive humans have not been published as of the time of this writing.

Evidence Strength: Evidence is predominantly in vitro and animal (non-human primate) for antiviral effects. No completed Phase II or III randomized controlled trials in human populations for antiviral indications have been reported in the peer-reviewed literature.

4.3 Toxic Shock Syndrome and Staphylococcal Toxin Inhibition

An in-depth clinical study concluded that GML applied on tampons (approximately 8 mg) was of great benefit to vaginal health by reducing Staphylococcus aureus exotoxin production and resulting vaginal pro-inflammatory interleukin 8 (IL-8) secretion. GML (250 µg/0.25 mL), when co-administered vaginally to rabbits with toxic shock syndrome toxin-1 (TSST-1), completely prevented TSST-1-induced Toxic Shock Syndrome after 24 hours.

In vitro, monolaurin has been shown to reduce the production of inflammatory cytokines by human vaginal epithelial cells and human T and B cells in response to superantigen and antigen stimulation, and to protect mammalian cells from exotoxin. In vivo studies in rhesus monkeys and humans have shown that monolaurin, but not vehicle control, significantly reduces cytokine production.

Evidence Strength: There is meaningful human and non-human primate evidence for topical GML reducing S. aureus exotoxin production in the vaginal environment. The tampon-based application represents one of the few direct human demonstrations of biological effect. However, controlled clinical endpoints (e.g., prevention of TSS episodes) have not been evaluated in large-scale human trials.

4.4 Bacterial Vaginosis Treatment

A Phase II multicenter randomized controlled trial evaluated the use of 5% monolaurin vaginal gel for the treatment of bacterial vaginosis (BV). This was a double-blinded, randomized controlled trial comparing 5% monolaurin vaginal gel to vehicle placebo (glycol-based) gel administered twice daily for 3 days. Nonpregnant, nonbreastfeeding women between ages 18 and 50 years were recruited and BV confirmed. 80 subjects received 5% Monolaurin Gel twice daily for three successive days for a total of 6 doses, and 40 subjects received placebo gel.

There was no significant difference in clinical cure for BV (p = .42), with 17% of the monolaurin group and 25% of the placebo group achieving clinical cure. Lactobacilli species counts increased in the monolaurin group compared with placebo (1.0 × 10⁷ vs −5.2 × 10⁶). Two thirds of both groups reported solicited urogenital adverse events, but these were mild to moderate with no significant difference between groups (p = .24). Monolaurin was no more clinically or microbiologically effective than placebo in curing BV. Future research should explore whether monolaurin may be used to increase Lactobacilli species.

Evidence Strength: The only completed Phase II randomized controlled trial for BV treatment found no significant clinical benefit over placebo for the 3-day dosing regimen tested. The evidence for this indication is therefore currently negative, though the favorable shift in Lactobacilli counts is a signal warranting further investigation with longer treatment durations.

4.5 Oral Antimicrobial and Nasal Decolonization

Only 3 peer-reviewed papers evidencing in vivo antimicrobial effects of monolaurin in humans were located in a comprehensive 2020 narrative review, and these were only for intravaginal and intraoral—that is, topical—use. One of these human applications was intranasal GML gel used for S. aureus anterior nares decolonization, which has been described in published literature but represents only a small clinical dataset.

A 2020 narrative review could find no peer-reviewed evidence regarding human clinical applications, therapeutic dosages, bioavailability, efficacy, or safety of GML as a dietary supplement other than the "generally recognized as safe" status granted by the FDA.

Evidence Strength: Weak for oral dietary supplement use. The available human evidence is limited to topical applications (intravaginal, intraoral). There are no randomized controlled trials of oral GML supplementation in humans for any indication.

4.6 Gut Microbiota and Intestinal Health

GML alleviates dextran sodium sulphate (DSS)-induced colitis by increasing the expression of anti-inflammatory cytokines (IL-10, TGF-β), and decreasing the expression of proinflammatory cytokines (TNF-α, IL-1β, IL-1α). One animal study demonstrated that GML modulated the composition of gut microbiota and short-chain fatty acid concentrations in a dose-dependent manner to improve intestinal health in mice.

One mouse study assessed the dose-dependent antimicrobial effects of GML on gut microbiota, glucose and lipid metabolism, and inflammatory response in C57BL/6 mice. Mice were fed diets supplemented with GML at doses of 400, 800, and 1600 mg/kg for 4 months. Results showed that supplementation of GML, regardless of the dosages, induced modest body weight gain without affecting epididymal/brown fat pad, lipid profiles, and glycemic markers. A high dose of GML (1600 mg/kg) showed positive impacts on the anti-inflammatory TGF-β1 and IL-22.

In C57BL/6 mice pretreated or cotreated with GML and in antibiotic-treated mice transplanted with GML-modulated microbiota, GML pretreatment had an advantage over GML cotreatment in alleviating weight loss and reducing disease activity index (DAI), colonic histological scores, and proinflammatory responses. GML-mediated enhancement of Bifidobacterium and fecal short-chain fatty acids (SCFAs) could be responsible for the anticolitis effect.

Evidence Strength: Evidence for gut microbiota modulation and anti-inflammatory effects in the gastrointestinal tract is entirely from in vitro and animal models (primarily mice). No human clinical trials on oral GML and gut health have been published in peer-reviewed literature.

4.7 Anti-inflammatory and Immunomodulatory Effects

GML is a potent antimicrobial agent that targets a range of bacteria, fungi, and enveloped viruses, but select findings suggest that GML also has immunomodulatory functions. GML showed immunomodulatory activities, as evidenced by inhibited T cell receptor (TCR)-induced production of the cytokines IL-2, IFN-γ, TNF-α, and IL-10.

In vitro studies showed that GML reduces T cell proliferation and activation following stimulation by T cell receptor (TCR) agonists, reducing the production of TCR-induced cytokines. The biological relevance of this immunosuppressive effect in the context of whole-body physiology at supplemental doses is uncertain, partly because of the albumin-binding phenomenon described below in the safety section.

Evidence Strength: Mechanistic immunomodulatory data is compelling at the cellular level (in vitro, human primary T cells), but translation to clinical outcomes in human subjects has not been demonstrated in controlled trials.

4.8 Human Breast Milk and Infant Protection

GML is a naturally occurring surfactant molecule abundant in human milk. It possesses antimicrobial activity against bacteria, fungi, and viruses. Research into GML's role in human breast milk represents its most biologically established natural context. GML prevents harmful pro-inflammatory processes in vivo at mucosal surfaces, although in vitro studies with purified GML show toxicity to tissue culture cells at concentrations ≥100 µg/mL.

Evidence Strength: The role of GML as a constituent of breast milk with antimicrobial and anti-inflammatory properties in that matrix is well established. GML's precise functional contribution to infant immunity within the complex milieu of breast milk (vs. its isolated form) is difficult to isolate experimentally.

5. Body Systems and Health Areas of Association

• Immune system: T-cell signaling modulation, cytokine regulation (IL-2, IFN-γ, TNF-α), and effects on innate and adaptive immune responses at mucosal surfaces.
• Reproductive/vaginal health: Inhibition of vaginal pathogens (Gardnerella vaginalis, Candida spp.), reduction of S. aureus exotoxin production, and investigated as a topical microbicide.
• Integumentary system (skin): GML has been utilized as a therapeutic agent in various clinical applications, including wound dressing, to inhibit the growth of exotoxin-producing bacteria.
• Gastrointestinal system: Modulation of gut microbiota composition, short-chain fatty acid production, and intestinal barrier function (currently animal-model evidence only).
• Antimicrobial/anti-infective: Broad-spectrum activity against bacteria, fungi, and enveloped viruses, with particular relevance to staphylococcal infections and toxin-mediated illness.
• Food preservation: GML is both an excellent emulsifier and a broad-spectrum antimicrobial agent in food.

6. Dosage Forms and Reported Dosages

Only 3 peer-reviewed papers evidencing in vivo antimicrobial effects of monolaurin in humans were located in a 2020 review, and these were only for intravaginal and intraoral—topical—use. No validated therapeutic dosage for oral supplementation has been established in controlled human trials.

Topical/Intravaginal Forms (Clinical Trials)

• The Phase II bacterial vaginosis clinical trial used 5% Monolaurin Gel administered twice daily for three successive days, for a total of 6 doses.
• In a clinical study using tampon-based delivery, approximately 8 mg of GML was applied per tampon for vaginal health assessment.

Preclinical (Animal) Dosages

• In mice, dietary GML was studied at doses of 400, 800, and 1600 mg/kg for 4 months to assess effects on gut microbiota, metabolism, and inflammation.
• A 5% monolaurin vaginal gel was used to prevent SIV transmission in 12 rhesus macaque monkeys in a preclinical study.

Oral Supplement Forms

Monolaurin is most commonly used as a nonionic surfactant and preservative in cosmetics and packaged foods. Monolaurin is also marketed as a dietary supplement. No peer-reviewed evidence was found in a 2020 review regarding therapeutic dosages of GML as an oral dietary supplement.

7. Safety Considerations and Interactions

Regulatory Status

The FDA has designated GML as Generally Recognized as Safe (GRAS) and it is incorporated in various products such as deodorants, lotions, and cosmetics. Chapter 21, Part 184 of the Code of Federal Regulations (CFR) includes monoglycerides among those compounds affirmed as GRAS (generally recognized as safe). Section 184.1505 of 21 CFR states further that monoglycerides, including GML, meet the specifications of the Food Chemicals Codex and can be used in food with no limitation other than current good manufacturing practice.

In Vitro Cytotoxicity vs. In Vivo Tolerability

In vitro studies with purified GML show toxicity to tissue culture cells at concentrations ≥100 µg/mL. The differences between in vivo versus in vitro activities have not been fully investigated, but may in part be related to the modulation of GML toxicity by human serum albumin. This distinction is important: laboratory concentrations demonstrating cytotoxicity may not correspond to physiologically relevant concentrations encountered during topical use or digestion.

Human Serum Albumin Interaction

In a published study examining how human serum albumin (HSA) affects GML-induced inhibition of human T cells, it was found that HSA and other serum albumins bind to the 12-carbon acyl side chain of GML at low micromolar affinities and restore TCR-induced formation of LAT, PLC-γ1, and AKT microclusters at the plasma membrane. HSA, one of the most abundant proteins in the human serum and at sites of infections, potently reverses the suppression of human T cells by GML. This suggests that GML-driven human T cell suppression depends upon the local tissue environment, with albumin concentration being a major determinant of GML function.

This interaction has practical implications: the immunomodulatory effects of GML observed in vitro may be substantially attenuated in systemic circulation, where albumin concentrations are high. Conversely, at mucosal surfaces (where albumin concentrations are lower), these effects may be more pronounced.

Drug Interactions via Albumin Binding

HSA binds to warfarin, azapropazone, furosemide, sulfisoxazole, diflunisal, etodolac, and lomefloxacin at affinities similar to GML, with dissociation constants between 2 to 6 µM. The degree of association between HSA and its ligands has a profound impact on the pharmaceutical activity of those compounds in that increasing concentrations of drug molecules bound to albumin result in decreased drug activity and vice versa. Direct drug displacement of albumin-bound warfarin and sulfonamide antibiotics by other albumin-binding compounds, which increases the pool of albumin-free warfarin and sulfonamides, decreases the drugs' effective dosage and potentiates possible toxic side effects. The clinical significance of these potential interactions at supplemental doses of GML has not been established in human studies.

Spermicidal Effect

Topically, GML is a spermicide, reducing both the motility and viability of sperm in the vaginal tract. Unfortunately, therapeutic indices comparing polarized epithelial cell toxicity with sperm toxicity for several surfactants, including GML, in vitro do not justify their use as contraceptive agents. This is a specific safety consideration for topical intravaginal use in women wishing to conceive.

Vaginal Adverse Events (Clinical Trial Data)

In the Phase II BV clinical trial, there was no difference between groups in solicited urogenital symptoms (p = .24), and all were mild to moderate in nature. No serious adverse events were reported. Short-course 5% monolaurin was well tolerated but no more effective than placebo in curing BV.

Absence of Resistance Development

Yearlong passage of S. aureus MN8 on sub-growth-inhibitory concentrations of GML did not produce any increase in resistance to its antimicrobial and anti-exotoxin effects. This represents a potentially favorable safety-adjacent characteristic compared to conventional antibiotics, though the clinical implications remain to be demonstrated in human settings.

Knowledge Gaps

A 2020 narrative review of the peer-reviewed literature could find no peer-reviewed evidence regarding human clinical applications, therapeutic dosages, bioavailability, efficacy, or safety of GML as a dietary supplement. Very little research has been done to study the effects of monolaurin supplements on the body, and their safety and benefits are not well defined. The absence of established oral bioavailability data in humans means that conclusions drawn from in vitro or topical studies cannot be straightforwardly extrapolated to oral supplement use.

References

• Zhang MS et al. "Glycerol Monolaurate (GML) inhibits human T cell signaling and function by disrupting lipid dynamics." Scientific Reports, 2016. PubMed/PMC.
• Zhang MS et al. "Glycerol Monolaurate (GML) inhibits human T cell signaling and function by disrupting lipid dynamics." Scientific Reports 6:30225, 2016. Nature.com.
• Hess DJ et al. "Antibacterial Synergy of Glycerol Monolaurate and Aminoglycosides in Staphylococcus aureus Biofilms." Antimicrob Agents Chemother, 2014. PMC.
• Schlievert PM, Peterson ML. "Glycerol Monolaurate Antibacterial Activity in Broth and Biofilm Cultures." PLoS ONE 7:e40350, 2012. PMC.
• Schlievert PM et al. "Glycerol Monolaurate (GML) and a Nonaqueous Five-Percent GML Gel Kill Bacillus and Clostridium Spores." mSphere, 2018. PMC.
• Schlievert PM et al. "Glycerol Monolaurate, an Analogue to a Factor Secreted by Lactobacillus, Is Virucidal against Enveloped Viruses, Including HIV-1." mBio, 2020. PMC.
• Schlievert PM et al. "Glycerol Monolaurate, an Analogue to a Factor Secreted by Lactobacillus, Is Virucidal against Enveloped Viruses, Including HIV-1." mBio, 2020. ASM Journals.
• Bakkum BW et al. "The Clinical Use of Monolaurin as a Dietary Supplement: A Review of the Literature." J Chiropr Med 18(4):305–310, 2020. PMC.
• Bakkum BW et al. "The Clinical Use of Monolaurin as a Dietary Supplement: A Review of the Literature." J Chiropr Med, 2020. ScienceDirect.
• Mo Q et al. "High-dose Glycerol Monolaurate Up-Regulated Beneficial Indigenous Microbiota without Inducing Metabolic Dysfunction and Systemic Inflammation." Nutrients 11(9):1981, 2019. PMC.
• He Y et al. "Glycerol monolaurate ameliorates DSS-induced acute colitis by inhibiting infiltration of Th17, neutrophils, macrophages and altering the gut microbiota." PMC, 2022.
• Novel Gut Microbiota Patterns Involved in the Attenuation of DSS-Induced Mouse Colitis Mediated by Glycerol Monolaurate. mBio, 2021. PMC.
• "Novel Gut Microbiota Patterns Involved in the Attenuation of Dextran Sodium Sulfate-Induced Mouse Colitis Mediated by Glycerol Monolaurate." mBio, 2021. ASM Journals.
• Zhang MS, Houtman JCD. "Human Serum Albumin (HSA) Suppresses the Effects of Glycerol Monolaurate (GML) on Human T Cell Activation and Function." PLoS ONE, 2016.
• Schlievert PM et al. "Glycerol Monolaurate Contributes to the Antimicrobial and Anti-inflammatory Activity of Human Milk." Scientific Reports 9:14550, 2019.
• Wang H et al. "Effects of dietary supplementation of glycerol monolaurate on laying performance, egg quality, antioxidant capacity, intestinal morphology and immune function in late-phase laying hens." PMC, 2024.
• Gould IM et al. "Unexpected Efficacy of Albumin-Bound Glycerol Monolaurate Against Multidrug-Resistant Bacterial Isolates: A Time-Kill Assay Study." PMC, 2025.
• Schlievert PM et al. "Antifungal, antibacterial, and anti-inflammatory activity of glycerol dithionomonolaurate, an analog of glycerol monolaurate." mSphere, 2025.
• Mancuso AC et al. "Five Percent Monolaurin Vaginal Gel for the Treatment of Bacterial Vaginosis: A Randomized Placebo-Controlled Trial." J Low Genit Tract Dis 24:277–283, 2020. ResearchGate.
• ClinicalTrials.gov: "Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis." NCT02709005.
• Wikipedia: Monolaurin. (Used for background cross-reference only; primary sources cited directly above.)
• U.S. Food & Drug Administration. "Generally Recognized as Safe (GRAS)." FDA.gov.
• Wang H et al. "Dietary Glycerol Monolaurate Effect on Growth Performance, Intestinal Barrier Function, and Gut Microbiota in Weaned Piglets Challenged by Lipopolysaccharide." Animals 15:3263, 2025. PMC.